Tectonic Therapeutic (TECX) Cash & Equivalents (2017 - 2026)

Tectonic Therapeutic (TECX) has 10 years of Cash & Equivalents data on file, last reported at $236.9 million in Q1 2026.

• On a quarterly basis, Cash & Equivalents fell 22.64% year-over-year to $236.9 million in Q1 2026; TTM through Mar 2026 was $236.9 million, a 22.64% decrease from a year earlier, with the FY2025 full-year figure at $253.8 million, up 79.69% from the prior year.
• Cash & Equivalents for Q1 2026 stood at $236.9 million, down from $253.8 million in the prior quarter.
• Over the last five years, Cash & Equivalents for TECX reached as high as $306.2 million in Q1 2025 and fell as low as $6.3 million in Q3 2023.
• Historically, Cash & Equivalents has averaged $146.0 million across 5 years, with a median of $141.2 million in 2024.
• Across the five-year window, Cash & Equivalents slumped 94.54% in 2023 and surged 2413.35% in 2024, its largest moves.
• Year by year, Cash & Equivalents stood at $92.6 million in 2022, then slumped by 68.92% to $28.8 million in 2023, then surged by 390.94% to $141.2 million in 2024, then jumped by 79.69% to $253.8 million in 2025, then declined by 6.66% to $236.9 million in 2026.
• Per Business Quant data, the three most recent Cash & Equivalents figures were $236.9 million in Q1 2026, $253.8 million in Q4 2025, and $268.4 million in Q3 2025.